Clinical trials: Interstitial Lung Diseases
Sarcoidosis
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
This study tests the safety and effectiveness of ustekinumab or golimumab compared to placebo (placebo looks like the drugs being studied, but has no active ingredients).
- Trial name
- NCT00955279
- Testing
- Golimumab, Ustekinumab
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 173 people
- Sponsor
- Centocor, Inc.
Interstitial Lung Diseases
Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
The purpose of this multi-centered, NIH-sponsored study is to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).
- Trial name
- NCT04855305
- Testing
- Hyperpolarized 129Xe
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Lung Diseases, Obstructive, Sarcoidosis
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
The purpose of this study is to evaluate the safety, effectiveness, and side effects of the CryoSpray AblationTM System (CryoSpray AblationTM, "CSA" or "cryospray therapy") to treat benign airway disease in the lung using liquid…
- Conditions
- Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma
- Trial name
- ICEtheBAD (NCT00747461)
- Testing
- CryoSpray Ablation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- CSA Medical, Inc.
Sarcoidosis, Pulmonary, Sarcoidosis Lung
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
This is a pilot study to determine whether further research is warranted to assess whether tofacitinib is an effective steroid sparing treatment for pulmonary sarcoidosis.
- Conditions
- Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
- Trial name
- NCT03793439
- Testing
- Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oregon Health and Science University
COPD, Interstitial Lung Disease
Autologous Stem Cell Treatment for Chronic Lung Disease Study
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day.
- Trial name
- NCT03044431
- Testing
- Cell therapy
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Lung Institute
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA
The purpose of this study is to investigate the safety and tolerability of two dose regimens of IFX-1 as add-on to standard of care (SOC) in subjects with GPA and MPA compared with placebo.
- Trial name
- NCT03712345
- Testing
- IFX-1 low dose, IFX-1 high dose
- Where
- 38 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- InflaRx GmbH
Idiopathic Pulmonary Fibrosis
Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine whether low concentration inhaled carbon monoxide is effective in treating idiopathic pulmonary fibrosis.
- Trial name
- NCT01214187
- Testing
- inhaled carbon monoxide, Oxygen
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Brigham and Women's Hospital
Idiopathic Pulmonary Fibrosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general.
- Trial name
- ISABELA1 (NCT03711162)
- Testing
- GLPG1690
- Where
- 132 sites in United States, Australia and 13 more
- Volunteers
- 525 people
- Sponsor
- Lakefront Biotherapeutics NV
Idiopathic Pulmonary Fibrosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
The main purpose of this study was to see how GLPG1690 works together with the current standard treatment on your lung function and IPF disease in general.
- Trial name
- ISABELA2 (NCT03733444)
- Testing
- GLPG1690
- Where
- 132 sites in United States, Argentina and 13 more
- Volunteers
- 781 people
- Sponsor
- Lakefront Biotherapeutics NV
Pulmonary Fibrosis, Anxiety
Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF
The purpose of the study is to assess efficacy and safety of a digital cognitive behavioural therapy for patients with pulmonary fibrosis on anxiety.
- Trial name
- COMPANION (NCT05330312)
- Testing
- Digital cognitive behavioral therapy
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- Vicore Pharma AB
Pulmonary Arterial Hypertension, Interstitial Lung Disease
A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
The purpose of this research study is to find out more about the drug treprostinil via inhaler and the mechanisms of why patients with pulmonary arterial hypertension related to Interstitial Lung disease (PAH-ILD) have…
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
- Trial name
- NCT05564637
- Testing
- Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Wegener's Granulomatosis
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys.
- Trial name
- NCT00468208
- Testing
- Abatacept
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Idiopathic Pulmonary Fibrosis
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
- Trial name
- IPF-201 (NCT04072315)
- Testing
- PLN-74809, Knottin tracer
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Pliant Therapeutics, Inc.
Langerhans Cell Histiocytosis
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.
- Trial name
- NCT02425904
- Testing
- Clofarabine
- Where
- 15 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Idiopathic Pulmonary Fibrosis, Cough
Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
Idiopathic Pulmonary Fibrosis (IPF) is a rapidly progressive lung disorder that is often associated with a chronic, intractable cough.
- Trial name
- NCT00600028
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Idiopathic Pulmonary Fibrosis
Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF)
Numerous studies show that remote monitoring and/or telenursing improves outcomes for patients especially those with chronic diseases.
- Trial name
- NCT03562247
- Testing
- Usual Care of IPF, Telenursing, Telenursing and Remote Monitoring
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University Medical Center
Idiopathic Pulmonary Fibrosis
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well…
- Trial name
- NCT01766817
- Testing
- BMS-986020
- Where
- 72 sites in United States, Australia and 4 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Transplant; Failure, Kidney, Renal Disease, End Stage
Oral Paricalcitol in Kidney Transplant Recipients
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this…
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- NCT00587158
- Testing
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Idiopathic Pulmonary Fibrosis
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study.
- Trial name
- NCT04419506
- Testing
- BI 1015550
- Where
- 75 sites in United States, Argentina and 20 more
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)